Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.57 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.57 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.57 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | CTRC | Q99895 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000634 | 1.00 | MAPT (0.57) | MAPTTLK2CDK5PTK2BCDK5R1 | |
| SCHEMBL3754998 | 0.78 | KDR (0.69) | MAPTCDK5SMN1; SMN2HTTEGFR | |
| SCHEMBL3754999 | 0.78 | KDR (0.69) | MAPTCDK5SMN1; SMN2HTTEGFR | |
| SCHEMBL5999814 | 0.75 | GSK3B (0.57) | MAPTTLK2CDK5MAPK1HTT | |
| SCHEMBL5999763 | 0.75 | GSK3B (0.54) | MAPTTLK2CDK5PTK2BCDK5R1 | |
| SCHEMBL5999765 | 0.75 | GSK3B (0.54) | MAPTTLK2CDK5PTK2BCDK5R1 | |
| SCHEMBL5999817 | 0.75 | GSK3B (0.57) | MAPTTLK2CDK5MAPK1HTT | |
| SCHEMBL14448901 | 0.74 | KDR (0.59) | MAPTPTK2BSMN1; SMN2MAPK1EGFR | |
| SCHEMBL5728271 | 0.74 | KDR (0.59) | MAPTPTK2BSMN1; SMN2MAPK1EGFR | |
| SCHEMBL5728269 | 0.74 | KDR (0.59) | MAPTPTK2BSMN1; SMN2MAPK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PFIZER INC | 2006-11-09 | — | — | US | disclosed |
| US-6906093-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1509224-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | Pharmacia Corporation (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6846839-B1 | Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis | SUGEN, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| WO-2003097044-A1 | METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030176487-A1 | 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | SUGEN, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-6469032-B2 | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION; ANTICARCINOGENIC, -DIABETIC, -PROLIFERATIVE AND -INFLAMMATORY AGENTS; VASCULAR SYSTEM DISORDERS | SUGEN, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020102608-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2002-08-01 | — | — | US | disclosed |
| US-20010027207-A1 | 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | TANG PENG CHO (US) | 2001-10-04 | — | — | US | disclosed |
| US-6225335-B1 | MODULATES TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION; FOR THERAPY OF CANCER, ATHEROSCLEROSIS, ARTHRITIS AND RESTENOSIS AND METABOLIC DISEASES SUCH AS DIABETES | SUGEN, INC. | 2001-05-01 | — | — | US | disclosed |
| EP-0934931-A2 | 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators | Sugen, Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5886020-A | MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5883113-A | TYROSINE KINASE INHIBITORS; ANTIPROLIFERATIVE AND ANTICARCINOGENIC AGENTS; DIABETES, ARTHRITIS, RESTENOSIS, ATHEROSCLEROSIS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5883116-A | ANTITUMOR AGENTS AND ENZYME INHIBITORS | SUGEN, INC. (US) | 1999-03-16 | — | — | US | disclosed |
| US-5834504-A | MODULATING, INHIBITING ABNORMAL CELL PROLIFERATION; ENZYME INHIBITION | SUGEN, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| EP-0769947-A4 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN INC (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5792783-A | CAPABLE OF MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION | SUGEN, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| EP-0769947-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | Sugen, Inc. (US) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996040116-A1 | INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE | SUGEN, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027207-A1 | 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | ERBB2, MKI67, ABL1 | MAPT 3103/4885TLK2 942/4885CDK5 22/4885 |
| US-20030176487-A1 | 3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease | ERBB2, MKI67, ABL1 | MAPT 3103/4885TLK2 942/4885CDK5 22/4885 |
| US-20020102608-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | PTPRJ, ERBB2, JAK2 | MAPT 1974/4885TLK2 618/4885CDK5 6/4885 |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | MAPT 4430/4885TLK2 2726/4885CDK5 105/4885 |
| US-20060252766-A1 | Methods using a combination of 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGES3 | MAPT 4608/4885TLK2 3163/4885CDK5 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.